

LEVIN & COMPANY, INC.
An Executive Search Firm



CHIEF FINANCIAL OFFICER

Position Profile

THE COMPANY

OncoGenex Pharmaceuticals is a NASDAQ traded biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has five product candidates in its pipeline, namely, OGX-011, OGX-427, OGX-225, SN2310 and CSP-9222, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

The Company has conducted five Phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer. Based on the Phase 2 results from 294 patients treated with OGX-011 (or over 300 patients if including patients in control groups), OncoGenex believes that both the prostate and lung cancer indications warrant development effort towards achieving marketing approval.

OncoGenex has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with castration-resistant prostate cancer (CRPC) via the Special Protocol Assessment (SPA) process. Additionally, in February of 2010, the European Medicines Agency notified OncoGenex that it was in general agreement with the development plan for OGX-011.

In December of 2009, OncoGenex entered into a global license and collaboration agreement to develop and commercialize OGX-011 with Teva Pharmaceutical Industries. Under the terms of the deal, OncoGenex received \$60 million in upfront payments and is eligible to receive up to \$370 million in additional cash payments as well as tiered royalties ranging from the mid-teens to mid-twenties. Additionally, Teva has committed to conducting three Phase 3 clinical trials: two Phase 3 trials in advanced prostate cancer to be initiated in Q2 and Q3 2010 and a Phase 3 trial in NSCLC to be initiated in early 2011.

Based on this agreement, OncoGenex has set the following corporate goals for OGX-011 in 2010:

- Q2 2010** Initiate Phase 3 trial evaluating OGX-011 with docetaxel retreatment as 2nd Line therapy in CRPC
- Q3 2010** Initiate Phase 3 trial evaluating OGX-011 with 1st Line docetaxel treatment in CRPC
- 2010** Publish Manuscripts for OGX-011 Phase 2 outcomes


The Company also established 2010 corporate goals regarding its other candidate in clinical development, OGX-427:

- 2010** Complete accrual from OGX-427 Phase 1 trial in solid tumors (monotherapy)
- 2010** Complete accrual from OGX-427 Phase 1 trial in solid tumors (with docetaxel)
- Q2 2010** Report final data from OGX-427 Phase 1 trial in solid tumors at ASCO Annual Meeting 2010
- 2010** Initiate randomized Phase 2 trial with OGX-427 as a monotherapy in prostate cancer

OncoGenex has offices in both Vancouver, British Columbia and Bothell, WA. The Company currently has 30 employees, with modest expansion plans for 2010 to support its performance obligations related to OGX-011.

PRODUCTS

OncoGenex has built a strong pipeline of oncology candidates through various licensing deals, including ones with the Vancouver Prostate Centre, and the 2008 reverse takeover of Sonus Pharmaceuticals. The result of these activities is a pipeline with five product candidates, three of which are supported by clinical data.



Product Candidates Overview and Recent Developments

OncoGenex’s product candidates OGX-011, OGX-427 and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to address treatment resistance by blocking the production of specific proteins which OncoGenex believes promote survival of tumor cells and are over-produced in response to a variety of cancer treatments. The Company’s aim in targeting these particular proteins is to disable the tumor cell’s adaptive defenses and thereby render the tumor cells more susceptible to attack with a variety of cancer therapies, including chemotherapy, which should increase survival time and improve the quality of life for cancer patients. Product candidate SN2310 is a novel camptothecin for the treatment of cancer. Camptothecins are potent anticancer agents that belong to the family of drugs called topoisomerase I inhibitors that bind reversibly to the TOPO-I-DNA complex causing breaks in the DNA strands during replication resulting in cell death. Product candidate CSP-

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

9222 is the lead compound from a family of compounds, which have been in-licensed from Bayer Healthcare LLC, that demonstrates activation of programmed cell death in pre-clinical models.

OGX-011

In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan (the "Clinical Development Plan") under which the following three Phase 3 clinical trials will be initiated:

- a 300-patient Phase 3 trial evaluating OGX-011 with docetaxel retreatment as second-line therapy in patients with Castrate Resistant Prostate Cancer (CRPC). Durable pain palliation is the primary endpoint for this trial. OncoGenex is in the process of opening sites for this trial and expects first patient treatment in Q2 of 2010, pending institutional review board approvals and patient screening. OncoGenex will have primary responsibility for the oversight of this trial;
- an 800-patient Phase 3 trial evaluating OGX-011 with first-line docetaxel treatment in patients with CRPC. Survival is the primary endpoint for this trial. OncoGenex presently anticipates that this trial will open in Q3 of 2010. Teva will have primary responsibility for the oversight of this trial; and
- a 700-patient Phase 3 trial evaluating OGX-011 with first-line chemotherapy in patients with Non-Small Cell Lung Cancer (NSCLC) to be initiated in early 2011. Teva will have primary responsibility for the oversight of this trial.

Supporting the Phase 3 and regulatory strategy is a robust pre-clinical data package and results from five Phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer. The Phase 2 clinical trials have treated 294 patients with OGX-011 (or over 300 patients if including patients in control groups). Data is available from each of the five Phase 2 studies which demonstrate that adding OGX-011 to therapy shows potential benefit of OGX 011.

Notably, final results of a randomized Phase 2 trial evaluating the benefit of combining OGX-011 with first-line docetaxel chemotherapy in patients with CRPC were presented during an oral presentation at the ASCO 2009 Annual Meeting. In this Phase 2 trial, patients were randomized to receive either docetaxel or OGX-011 plus docetaxel.

The trial enrolled 82 patients at 12 sites in Canada and the United States from September 2005 to December 2006. Patients were randomized to one of two

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

treatment arms to receive either 640 mg per week of OGX-011 by intravenous infusion in combination with docetaxel and prednisone or docetaxel and prednisone alone. Patients in both treatment arms received therapy until disease progression, toxicity or the completion of ten 3-week cycles of therapy. Analyses indicated a survival benefit in patients treated with OGX-011 in combination with docetaxel compared to docetaxel alone - the current standard care for patients with advanced prostate cancer:

- The median overall survival in patients who were treated with OGX-011 plus docetaxel trial was 23.8 months compared to 16.9 months for patients treated with docetaxel alone, indicating a 6.9 month survival advantage in the OGX-011 arm;
- The unadjusted hazard ratio ("HR"), a measure used to compare the death rates between treatment groups, was 0.61, representing a 39% lower rate of death for patients treated with OGX-011; and
- A prospectively defined multivariate analysis indicated that the significant predictors of overall survival were treatment arm, performance status and presence of metastases other than in bone or lymph nodes. In the multivariate analysis, patients treated with OGX-011 had a rate of death of 51% lower than patients treated with docetaxel alone (HR=0.49; p=0.012). Additional exploratory analyses found that the lower rate of death was associated with the effect of OGX-011 treatment even when varying amounts of chemotherapy were administered (i.e. OGX-011 treatment resulted in a lower rate of death when compared to the control arm for patients receiving 6 or less cycles of chemotherapy as well as for patients receiving 10 cycles of chemotherapy).

OGX-427

OGX-427, an inhibitor of heat shock protein 27, is being evaluated in a Phase 1 clinical trial to evaluate safety for OGX-427 administered alone, as well as in combination with docetaxel chemotherapy ("docetaxel"), in patients with various types of cancer. Enrollment in the OGX-427 monotherapy aspect of the Phase 1 clinical trial is complete. Enrollment in the OGX-427 in combination with docetaxel aspect of the clinical trial is ongoing. A second investigator-sponsored Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer was initiated in August 2009. The study, which will enroll up to 36 patients with bladder cancer, is designed to determine the safety and potential benefit of OGX-427 administered directly into the bladder using a catheter, which is known as intravesical instillation. In addition, the study will measure the direct effect of OGX-427 on expression of Hsp27 in bladder tumor cells as well as determine the pharmacokinetics and pharmacodynamics of OGX-427 when delivered by intravesical instillation.

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

In January 2010, OncoGenex announced that an investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with CRPC has received grant funding. The randomized, controlled Phase 2 study will enroll up to 72 patients and is designed to determine the potential benefit of OGX-427 by evaluating the number of patients who are without disease progression at 12 weeks post-study treatment, with or without OGX-427.

SN2310, OGX-225 and CSP-9222

SN2310 was evaluated in a Phase 1 clinical trial to evaluate safety in patients with advanced cancer who have received on average 3 to 5 prior chemotherapy treatments. The Phase 1 clinical trial has been completed. The Company is currently exploring options to out-license this product candidate.

OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5, and CSP-9222 are in pre-clinical development.

MANAGEMENT

Scott Cormack President & Chief Executive Officer

Mr. Scott Cormack has over two decades of diverse experience in the biotechnology industry in executive management and venture capital. Scott is the founding President and CEO of OncoGenex Technologies Inc. and became its full-time President and CEO in January, 2002. He has led OncoGenex through significant corporate milestones including serial rounds of private financing; leading the corporation through transition from pre-clinical through completion of multiple Phase 2 clinical trials and through the development of a robust product candidate pipeline. In August, 2008 OncoGenex Technologies Inc. completed a successful reverse take over of Sonus Pharmaceuticals, Inc. to become a NASDAQ listed biotechnology company with Scott becoming the Chief Executive Officer of OncoGenex Pharmaceuticals, Inc. In October, 2009, Scott was named Canada's Pacific Ernst & Young's Entrepreneur of the Year®, a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses. In December, 2009, Scott led his team to complete a global collaboration and license agreement with global generic medicines giant, Teva Pharmaceutical Industries Ltd., to support the final stage of development of OGX-011. Scott has created a solid foundation for OncoGenex to maximize the broad potential of OGX-011 and a robust pipeline of product candidates, potentially bringing important treatment options to cancer patients.

Cindy Jacobs Ph.D., M.D. Executive Vice President and Chief Medical Officer

Dr. Jacobs is Executive Vice President and Chief Medical Officer at OncoGenex. She received her Ph.D. from Washington State University and her M.D. from the University of Washington Medical School. She has over twenty years of biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, Phase 1-4 clinical trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance. At Immunex (now known as Amgen), Dr. Jacobs successfully lead the preclinical development of soluble cytokine receptors and fusion proteins into the clinic which later resulted in the approval of the TNF Receptor Fusion protein for use in rheumatoid arthritis, currently on the market as Enbrel. Subsequently, she became Vice-President of Clinical Research at CellPro Inc. and coordinated an international team achieving both European and US approvals of the CEPRATE SC Stem Cell System for use in bone marrow and peripheral blood transplantation. Her team achieved two US approvals for the CEPRATE SC System, as a device in combination with a

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

monoclonal antibody for selection of CD34+ cells. Prior to joining OncoGenex, Dr. Jacobs was the Senior Vice-President of Clinical Development and Chief Medical Officer at Corixa (now a subsidiary of Glaxo-Smith-Kline). During her six years at Corixa, her team obtained Canadian approval for Melacine, a cancer vaccine for Melanoma, and two US approvals for BEXXAR, a radioimmunotherapy for refractory and relapsed non-Hodgkin's lymphoma.

Monica Krieger Ph.D.
Vice President of Regulatory Affairs

Dr. Krieger is Vice President, Regulatory Affairs at OncoGenex. She received a Ph.D from Rutgers University and an MBA from the Darden School at the University of Virginia. Her 24 years of experience in regulatory and clinical affairs includes 23 years at five biotechnology companies in Seattle. At Genetic Systems Corporation (currently owned by BioRad Laboratories) she was Vice President, Regulatory, Clinical and Quality Assurance. During her nine years there she led a team that obtained approval for blood banking tests for HIV-1, HIV-2 and hepatitis, as well as approval of other tests for infectious disease. Subsequently she spent seven years at CellPro, Inc. where she worked with Dr. Jacobs to obtain two approvals from the FDA for the CEPRATE ® SC, a stem cell selection device. The first approval was based on data from patients with breast cancer and the second demonstrated the utility of the device in tumour removal in patients with multiple myeloma. At NeoRx, Dr. Krieger led the regulatory group developing two oncology products: one for the treatment of non-Hodgkin's lymphoma and the second for multiple myeloma. Most recently, she spent six years at Corixa Corporation as Vice-President, Regulatory Affairs. There she worked with Dr. Jacobs, and the clinical/regulatory team obtained Canadian approval for Melacine, a vaccine for the treatment of melanoma as well as two US approvals for BEXXAR, a radioimmunotherapy for non-Hodgkin's lymphoma.

Martin Gleave M.D., FRCSC, FACS
Chief Scientific Advisor

Dr. Gleave is a consultant of OncoGenex Technologies and its Chief Scientific Advisor, previously serving as contract Chief Scientific Officer from May 2000 to March 2010. Dr. Gleave is co-founder of OncoGenex Technologies and the principal inventor of its product candidates, OGX-011, OGX-427, and OGX-225. He also served as a director of OncoGenex Technologies prior to the reverse takeover of Sonus Pharmaceuticals. Dr. Gleave is a Distinguished Professor and Director of Research in the Department of Urologic Sciences at the University of British Columbia ("UBC"), the British Columbia Leadership Chair in Prostate

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

Cancer Research, and a consultant Urologist for the Department of Urology at the University of Washington. Dr. Gleave is a Senior Research Scientist and Director of the Vancouver Prostate Center, a UBC and National Centre of Excellence and internationally respected integrated prostate cancer research and treatment facility. Dr. Gleave's major research focus involves the study of cellular and molecular mechanisms mediating acquired treatment resistance in prostate and other cancers, and use of this information to develop integrated multimodality therapies that specifically target these mechanisms. Dr. Gleave directs a translational cancer research program spanning target discovery, validation, credentialization, and therapeutic development and has characterized the functional role of many survival genes in cancer progression, leading to several patented targeted inhibitors. Dr. Gleave received his M.D. from the University of British Columbia in 1984, his Fellow at the Royal College of Surgeons of Canada (FRCSC) in 1989, his Urologic Oncology Fellowship, University of Texas MD Anderson Cancer Center in 1992 and Fellow of the American College of Surgeons (FACS) in 1998.

BOARD OF DIRECTORS

On March 24, 2010, the Company announced the appointment of Jack Goldstein and Stewart Parker to the Board of Directors. Jack Goldstein was also appointed as Chairman of the Board. The Company also announced that Michael Martino and Dwight Winstead will not be seeking re-election and that Martin Mattingly has agreed to stand for election at the Company's upcoming AGM. The present Board of Directors is as follows:

Jack Goldstein, Ph.D

Chairman

Former President and Chief Operating Officer, Chiron Corporation

Jack Goldstein, Ph.D., has served as Chairman of the Board of Directors of the Company since March 2010. Dr. Goldstein was President and Chief Operating Officer of Chiron Corporation until its acquisition by Novartis in April 2006. Before Chiron, he spent two years as a general partner at Windamere Venture Partners, preceded by four years at Applied Imaging Corporation, first as president and Chief Executive Officer and later as chairman. Dr. Goldstein spent over a decade at Ortho Diagnostic Systems, a Johnson & Johnson company, in various executive positions, including four years as president. He was earlier vice president of research and development at a division of Baxter Healthcare Corporation. Dr. Goldstein earned a bachelor of art degree in biology from Rider University, a Master of Science degree in immunology, and doctorate in microbiology from St. John's University. He currently sits on the board of directors of Illumina, Inc., and Orasure Technologies Inc.

Scott Cormack

President & Chief Executive Officer, OncoGenex Pharmaceuticals Inc.

See biography above.

Neil James Clendeninn Ph.D., M.D.

Retired Vice President and Head, Clinical Affairs, Agouron Pharmaceuticals

Dr. Clendeninn served as Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., from 1993 until his retirement in 2001. With Agouron, Dr. Clendeninn was responsible for development and growth of the Clinical Development Department from pre-clinical Phase to Phase IV, rapid delivery to market for Viracept, an HIV Protease Inhibitor. Under his leadership, the department grew to over 200 MDs, Ph.Ds and clinical pharmacologists, biostatisticians, data management group and a post

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

marketing medical team. Previous to Agouron, Dr. Clendeninn served as Director of the Clinical Oncology Department for Burroughs Wellcome Company. His other past positions include assistant clinical professor in oncology at the University of North Carolina, senior staff member at the National Cancer Institute, and other general practice and academic-based positions. Dr. Clendeninn has led extensive research in areas that include chemotherapeutic multi-drug resistance, opiate receptors and photochemistry. Dr. Clendeninn holds a BA Biology/Chemistry from Wesleyan University, CT, and a Ph.D Microbiology/Pharmacology and M.D. from New York University, NY.

Michael A. Martino

Senior Vice President of Innovation, Business Development and Strategy, CareFusion

Michael Martino has been a director of the Company (previously Sonus Pharmaceuticals, Inc. ("Sonus")) since September 1998. Mr. Martino is currently the SVP of Innovation, Business Development and Strategy of CareFusion. Prior to his position at CareFusion, he was the Chief Executive Officer of Arzeda Corp. Mr. Martino was the President and Chief Executive Officer of Sonus from July 1999 until the reverse takeover of Sonus by OncoGenex Technologies Inc. in August 2008. From September 1998 to July 1999, he was the President and Chief Operating Officer of Sonus. From 1983 to 1998, Mr. Martino held numerous positions of increasing responsibility in strategic planning, business development, marketing and sales, and general management with Mallinckrodt, Inc., a global healthcare products company, including serving as Vice President and General Manager of the Nuclear Medicine Division. Mr. Martino holds a B.A. in business from Roanoke College and an M.B.A. from Virginia Tech. He sits on the Presidents Advisory Board of Roanoke College and is a member of the Board of Trustees of Cascadia Community College. In addition, Mr. Martino is a past Chairman of the Board of the Washington Biotechnology and Biomedical Association (WBBA). Mr. Martino is not seeking re-election to the Board of Directors at the Company's upcoming AGM.

Michelle Burris

Senior Vice President and Chief Operating Officer, Trubion Pharmaceuticals

Ms. Burris has been a director of the Company since May 2004. Ms. Burris is currently Senior Vice President and Chief Operating Officer of Trubion Pharmaceuticals, Inc, a position she has held since November 2009. From February 2006 to November 2009 she served as Senior Vice President and Chief Financial Officer. From August 2005 to January 2006, Ms. Burris served as

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

Senior Vice President and Chief Financial Officer at Dendreon Corporation. From January 2001 to July 2005, she served as Senior Vice President and Chief Financial Officer at Corixa Corporation, which was sold to GlaxoSmithKline in 2005. Ms. Burris had worked at Corixa since its inception in 1994, and prior to her last position at the firm, had served in various capacities of increasing responsibility in finance and operations. Prior to Corixa, Ms. Burris held several finance and strategic planning positions at The Boeing Company. Ms. Burris is on the Advisory Board of Albers School of Business and Economics at Seattle University. She received a Post Graduate Certificate in accounting and an MBA from Seattle University, and a B.S. from George Mason University. Ms. Burris received her Certified Public Accountant Certification from the State of Washington; however, she is no longer an active CPA.

H. Stewart Parker

Former President and Chief Executive Officer, Targeted Genetics

Stewart Parker has served as a director of the Company since March 2010. Ms. Parker managed the formation of Targeted Genetics as a wholly owned subsidiary of Immunex Corporation (Immunex was subsequently acquired by Amgen) and served as President, Chief Executive Officer and a director of Targeted Genetics since its spinout from Immunex in 1992 to 2008. She served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. Ms. Parker also served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products, from February 1991 to January 1993. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry, and as a director of several privately held companies. Ms. Parker received her B.A. and M.B.A. from the University of Washington.

Dwight Winstead

Chief Operating Officer, Carefusion

Mr. Winstead has served as a director of Sonus since July 1995. Mr. Winstead is currently Chief Operating Officer of Carefusion which was spun out of Cardinal Health Clinical Technologies and Services. Previously, Mr. Winstead was President and Chief Operating Officer of Cardinal Health Clinical Technologies and Services, (CTS) a subsidiary of Cardinal Health, Inc. Prior to his current position at CTS, he served as Group President of Clinical Services and Consulting and President of Pyxis Products, formerly known as AIS (Automated Information Services) since 1997. From 1991 to 1997, Mr. Winstead served as Executive Vice President of VHA, Inc., a performance improvement company

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

serving health care organizations in the United States. Prior to his promotion to Executive Vice President, Mr. Winstead served in various capacities of VHA Supply Company, a subsidiary of VHA, Inc., including Vice President, Sales and Marketing, Senior Vice President, Chief Operating Officer and President from 1987 to 1991. Prior to joining VHA, Inc. in 1984, Mr. Winstead served in a variety of materials management and sales positions in several companies, including Ortho Instruments and Worthington Diagnostics. Mr. Winstead holds a B.S. from Delta State University. Mr. Winstead is not seeking re-election to the Board of Directors at the Company's upcoming AGM.

New Board Candidate Standing for Election at Company's Upcoming AGM

Martin A. Mattingly, Pharm.D. Chief Executive Officer, Trimeris, Inc.

Martin A. Mattingly, Pharm.D., joined Trimeris as Chief Executive Officer in November 2007. Dr. Mattingly was most recently President and Chief Executive Officer of Ambrx Pharmaceuticals. Prior to Ambrx, Dr. Mattingly served as Executive Vice President and Chief Operating Officer at CancerVax. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals and Pfizer. Dr. Mattingly previously served as Vice President, Product Development Group for Pfizer, and Vice President of Global Marketing, Senior Director of Marketing and Director of Product Marketing for Agouron. At Agouron he was a part of the senior management team that created a sales and marketing organization for the launch of VIRACEPT® for AIDS, which had peak sales of over \$400 million. Prior to joining Agouron, Dr. Mattingly worked at Eli Lilly and Company in management positions in oncology and CNS (central nervous system) marketing, where he led the development of a new oncology sales and marketing organization and launched Gemzar® for pancreatic cancer. While at Lilly, Dr. Mattingly also undertook marketing programs for new Prozac® indications. Dr. Mattingly has a Doctor of Pharmacy degree from the University of Kentucky.

THE POSITION

The Chief Financial Officer supports the President and CEO and the Senior Management Team in reaching the Company's financial objectives by delivering accurate financial reporting; budgeting; forecasting; financial and operational analysis; and maintenance of cash flow.

The key objective will be to direct the firm's financial operations and establish improved overall financial policies, practices and methodologies required to operate in today's environment. The CFO will oversee treasury, accounting, budget, tax and audit activities. The successful hire will also be involved in investor relations and have other departments reporting into them.

Located in Vancouver and reporting to the CEO, responsibilities of this new CFO will include overseeing the accounting functions of the corporate office, managing the board of directors and board committee schedules to ensure timely reporting and compliance with various filing requirements, managing other non-accounting aspects of the business and managing Wall Street relationships. These responsibilities will include managing corporate governance, leading the budgeting process, conducting financial and strategic analysis, handling investor relations, financial and statutory reporting, improving internal controls, managing due diligence and financial integration of acquisitions. The CFO will lead a dynamic financial support team, initially with four direct reports, to provide accurate and timely information to the Company. When circumstances and deadlines require it, the position requires a hands-on approach with your team. Inherent with the position is the responsibility of ensuring the corporation maintains compliance with its various securities and regulatory authorities.

More specifically, The Chief Financial Officer will be responsible for:

- Maintaining and improving financial reporting systems with controls and standards to safeguard Company assets in compliance with Sarbanes-Oxley Act and other fiduciary reporting required of a publicly traded company.
- Providing financial leadership and strategic advice in the development of financial policies and procedures in a manner that supports the achievement of the Company's strategic and operating goals and objectives.
- Ensuring that there is a broad sense of financial discipline applied to all officers and employees.
- Maintaining, improving and implementing, as required, accounting policies, procedures and internal controls appropriate to current stage and near term growth objectives of the Company.

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

- Overseeing the Company's financial and budgetary planning process, mentoring staff on budgetary process and procedures, and regularly reviewing performance against plan.
- Co-managing (with the CEO), relationships with our potential and current business partners (ie Teva, Isis).
- Ensuring that appropriate due diligence has been carried out prior to the Company committing to a course of action where the Company is expending funds or committing to a contractual obligation.
- Tax planning and compliance, cost containment, analysis and development of opportunities regarding acquisitions or divestitures and contract negotiations with suppliers or partners.
- Endorsing all financial information as to its completeness, reliability and accuracy submitted to the Board of Directors, any public sector agency, investors and other stakeholders.
- Interpreting, analyzing and presenting financial and related information for senior management and/or the Board of Directors, in order to facilitate understanding of issues and options, and to guide appropriate decisions.
- Establishing and maintaining sound relationships with investors, financial institutions, auditors and investment bankers.
- Co-leading (with the CEO) negotiations with potential and current investors, financial institutions and/or investment bankers as directed by the CEO and/or Board of Directors.
- Communicating with Analysts in a timely manner with high standards of clarity and quality which builds trust with the Analysts by demonstrating a sound grasp of operational details and delivering a solid track record of accurate numbers.
- Acting as the primary Management contact for the audit committee, communicating actively with them and ensuring audit committee members have necessary and accurate information related to the organization and the committee's responsibilities.
- Managing overall corporate governance activities including compliance with securities regulations, shareholder and investment agreements, and other contractual or legislative obligations of the corporation.
- Overseeing business development activities with particular consideration of strategic fit, financial and contractual obligations of agreements, and impact on financial and human resources of the company.
- Facilitating a timely due diligence process as necessary to secure additional capital and strategic partnerships.
- Identifying and managing business risks and insurance requirements and develops rigorous processes to avoid surprises.
- Ensuring that direct reports have clearly defined roles, understand personal and corporate priorities, and receive appropriate mentoring to enhance individual performance towards corporate objectives.

- Hiring, retaining and developing internal talent within the finance department.
- Performance Management of the Accounting Team.
- Other duties as required.

SHORT TERM GOALS

- Study and learn the product candidates, data package for each and the solid tumor oncology space, with particular focus on prostate cancer
- Review the operations of the finance department, accounting policies and procedures and corporate governance policies
- Establish working relationships with all staff in the Company, understanding the operations of the business and general operating environment
- Establish working relationships with all members of the board of directors
- Study the Company's key agreements with licensees, licensors and vendors
- Study the Company's shareholder base and institutional investor meeting history including non-deal roadshows and establish key Wall Street relationships with current and prospective analysts, investment banking teams and institutional investors.
- Review the board and board committee meeting calendars and establish a working plan to ensure management of the board and committees for seamless delivery of key compliance filings (10Q's, 10K, Proxy, etc.).

LONG TERM GOALS

- Continued expansion and execution of the short term goals above.
- Control the financial/accounting functions in a way acceptable to external auditors with regards to best practices and standards.
- Put strategic and tactical financial plans in place to ensure adequacy of financial resources to achieve the Company's clinical and commercialization objectives.
- As part of the Senior Management team, contribute to a strategic planning process to establish a strategic plan designed to achieve substantial growth and commercial success utilizing diverse tools such as partnering, licensing, M&A, financing, etc.

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

- As part of the Senior Management team, present the Company from a financial perspective to all relevant constituencies (investors, bankers, etc.) so as to ensure awareness, interest in future equity financings and/or stock support.

PROFESSIONAL QUALIFICATIONS

- CPA required and an MBA preferred (finance) or equivalent business experience; scientific undergraduate degree an asset to this position.
- Minimum of 10 years in finance and operations at the corporate level within publicly held companies and have experience in treasury, control, accounting, cash management, corporate development and accounting related systems.
- Direct experience with raising capital.
- Experience with filings required under Sarbanes-Oxley regulations.
- Knowledge of financial reporting requirements, internal controls, corporate governance and audit procedures.
- Proven experience with transaction structuring including mergers and acquisitions, licensing agreements, joint ventures, etc. is essential.
- A reputation in the US business community as an outstanding financial executive.
- Experience managing board of directors and committees to ensure timely reporting and compliance with securities regulations.

PERSONAL QUALIFICATIONS

- As the responsibilities and influence of the CFO change, it is important that the CFO effectively communicates on financial and strategic matters, provides high-level leadership, and has effective change management skills.
- Strong analytical, strategic planning and communication skills, and the ability to work well with the CEO, Board members, investors and other members of the Management team.
- Although the CFO will be a confidante to the CEO, s/he should nonetheless be the type of executive who has the vision to originate ideas, the confidence to take a stand on a position, and the desire to be an active contributor to the thinking that drives the business rather than a de facto

This report is a private document and contains information that is privileged or confidential. It is to be used only in conjunction with the recruiting activities being conducted by Levin and Company for OncoGenex Pharmaceuticals, Inc.

endorser of the views of the CEO and other members of the leadership team.

- Understands that responsibilities will change over time and has the breadth of capabilities to allow effective leadership in other areas of the organization.
- Has the ability to see and articulate the big picture and is able to anticipate and identify significant future issues and trends.
- Must have a strong negotiation style and personality built upon ethical and sound business philosophies which aid the organization in guiding the implementation of a variety of strategies.
- Strong intellectual capacity, reflected in sound reasoning, superior analytical talents, mature judgment and incisive self-expression.
- Strong written and verbal communication skills coupled with excellent presentation skills.
- Entrepreneurial spirit.

COMPENSATION

- Base salary
- Bonus by objective
- Stock Options
- Attractive relocation and benefits package